Exploring potential noninvasive biomarkers in eosinophilic esophagitis in children

Journal of Pediatric Gastroenterology and Nutrition

Volumn 53, Issue 6, 2011, Pages 651-658

  Subbarao, Girish ^a   Rosenman, Marc B ^a   Ohnuki, Lyo ^b   Georgelas, Ann ^b   Davis, Miriam ^a   Fitzgerald, Joseph F ^a   Molleston, Jean P ^a   Croffie, Joseph M ^a   Pfefferkorn, Marian D ^a   Corkins, Mark R ^a   Lim, Joel R ^a   Steiner, Steven J ^a   Schaefer, Elizabeth ^c   Gleich, Gerald J ^b   Gupta, Sandeep K ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c ST VINCENT HOSPITAL   (United States)

Author keywords

biomarkers; eosinophilic esophagitis; pediatrics

Indexed keywords

BIOLOGICAL MARKER; EOSINOPHIL PROTEIN X; FLUTICASONE; INTERLEUKIN 5; PREDNISONE;

ARTICLE; ATOPY; BLOOD ANALYSIS; CHILD; CLINICAL EXAMINATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; EOSINOPHILIC ESOPHAGITIS; ESOPHAGOGASTRODUODENOSCOPY; FECES ANALYSIS; FEMALE; FOOD ALLERGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; TREATMENT DURATION;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; ENDOSCOPY, DIGESTIVE SYSTEM; EOSINOPHIL-DERIVED NEUROTOXIN; EOSINOPHILIC ESOPHAGITIS; EOSINOPHILS; FEMALE; HUMANS; INTERLEUKIN-5; LONGITUDINAL STUDIES; MALE; PHENOTYPE; PROSPECTIVE STUDIES;

EID: 82355182107     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318228cee6     Document Type: Article

References (24)

1. Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007;133:1342-63.
2. Spergel JM, Brown-Whitehorn TF, Beausoleil JL, et al. 14 years of eosinophilic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol Nutr 2009;48:30-6.
3. Gupta SK. Noninvasive markers of eosinophilic esophagitis. Gastro-intest Endosc Clin N Am 2008;18:157-67. (Pubitemid 350166937)
4. Straumann A, Kristl J, Conus S. Cytokine expression in healthy and inflamed mucosa: probing the role of eosinophils in the digestive tract. Inflamm Bowel Dis 2005;11:720-6. (Pubitemid 41271175)
5. Blanchard C, Wang N, Stringer KF, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 2006;116:536-47. (Pubitemid 43228372)
6. Gupta SK, Fitzgerald JF, Kondratyuk T, et al. Cytokine expression in normal and inflamed esophageal mucosa: a study into the pathogenesis of allergic eosinophilic esophagitis (AEE). J Pediatr Gastroenterol Nutr 2006;42:22-6. (Pubitemid 43061005)
7. Konikoff MR, Blanchard C, Kirby C, et al. Potential of serum eosino-phils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006;4:1328-36. (Pubitemid 44716743)
8. Hogan SP, Foster PS, Rothenberg ME. Experimental analysis of eosi-nophil-associated gastrointestinal diseases. Curr Opin Allergy Clin Immunol 2002;2:239-48. (Pubitemid 34615118)
9. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006; 24:147-74.
10. Slifman N, Loegering DA, McKean DJ, et al. Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol 1986;137:2913-7. (Pubitemid 17177799)
11. Saitoh O, Kojima K, Sugi K, et al. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. Am J Gastroenterol 1999;94:3513-20.
12. Yang D, Chen Q, Rosenberg H, et al. Human ribonuclease a superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. J Immunol 2004;173: 6134-42. (Pubitemid 39487770)
13. Levy AM, Yamazaki K, Van Keulen VP, et al. Increased eosinophil infiltration and degranulation in colonic tissue from patients with collagenous colitis. Am J Gastroenterol 2001;96:1522-8. (Pubitemid 32455084)
14. Menies-Gow A, Robinson DS. Eosinophil chemokines and their receptors: an attractive target in asthma? Lancet 2000;355:1741-3. (Pubitemid 30265075)
15. Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008;6:165-73. (Pubitemid 351172942)
16. Abu-Ghazaleh RI, Dunnette SL, Loegering DA, et al. Eosinophil granule proteins in peripheral serum granulocytes. J Leukoc Biol 1992;52:611-8. (Pubitemid 23016034)
17. Kim KW, Lee KE, Kim ES, et al. Serum eosinophil-derived neurotoxin (EDN) in diagnosis and evaluation of severity and bronchial hyper-responsiveness in childhood asthma. Lung 2007;185:97-103. (Pubitemid 46571877)
18. Hidaka Y, Kimura M, Izumi Y, et al. Increased serum concentration of eosinophil-derived neurotoxin in patients with Graves' disease. Thyroid 2003;13:129-32. (Pubitemid 36596709)
19. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358:1215-28. (Pubitemid 351439223)
20. Lowchik A, Weinberg AG. A quantitative evaluation of mucosal eosinophils in the pediatric gastrointestinal tract. Mod Pathol 1996; 9:110-4. (Pubitemid 26092098)
21. Ngo P, Furuta GT, Antonioli DA, et al. Eosinophils in the esophagus-peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol 2006;101:1666-70.
22. Dranove JE, Horn DS, Davis MA, et al. Predictors of response to proton pump inhibitor therapy among children with severe esophageal eosi-nophilia. J Pediatr 2009;154:96-100.
23. Stein ML, Collins MH, Villanueva JM, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2006;118: 1312-9. (Pubitemid 44872890)
24. Straumann A, Conus S, Simon H, et al. Mepolizumab, a humanized monoclonal antibody to IL-5, for severe eosinophilic esophagitis in adults: a randomized, placebo-controlled double-blind trial. Gastroen-terology 2007;132:2586.